Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3368632 | 0.91 | KMT2A (0.44) | SIRT2SIRT1MEN1KMT2AALDH1A1 | |
| SCHEMBL9856677 | 0.91 | KMT2A (0.44) | SIRT2SIRT1MEN1KMT2AALDH1A1 | |
| SCHEMBL9856603 | 0.89 | SIRT2 (0.52) | SIRT2SIRT1SIRT3FOLH1ACE | |
| SCHEMBL5346764 | 0.85 | SMN1; SMN2 (0.46) | SIRT2SIRT1MEN1KMT2AACE | |
| SCHEMBL15101628 | 0.82 | MME (0.45) | SIRT2SIRT1FOLH1ACE | |
| SCHEMBL901542 | 0.82 | MME (0.45) | SIRT2SIRT1FOLH1ACE | |
| SCHEMBL901541 | 0.82 | MME (0.45) | SIRT2SIRT1FOLH1ACE | |
| SCHEMBL14423532 | 0.79 | SMN1; SMN2 (0.48) | MEN1KMT2AALDH1A1HPGDACE | |
| SCHEMBL8622468 | 0.77 | KMT2A (0.53) | MEN1KMT2AALDH1A1NPC1ACE | |
| SCHEMBL28547510 | 0.77 | KMT2A (0.53) | MEN1KMT2AALDH1A1NPC1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093664-A1 | Process for the production of lisinopril | ECZACIBASI-ZENTIVA KIMYASAL URUNLER SANAYI VE TICARET A.S. (TR) | 2007-04-26 | — | — | US | disclosed |
| EP-1513868-B1 | PROCESS FOR THE PRODUCTION OF LISINOPRIL | EOS ECZACIBASI OZGUN KIMYASAL (TR) | 2006-08-09 | — | — | EP | disclosed |
| EP-1513868-A1 | PROCESS FOR THE PRODUCTION OF LISINOPRIL | EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. (TR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004000874-A1 | PROCESS FOR THE PRODUCTION OF LISINOPRIL | EOS ECZACIBASI OZGUN KIMYASAL URUNLER SANYI VE TI CARET A.S. (TR) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093664-A1 | Process for the production of lisinopril | ACE, LOX, AGT | SIRT2 2922/4885SIRT1 2976/4885MEN1 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.